Literature DB >> 28236575

Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.

Vitor Carmona1, Janete Cunha-Santos1, Isabel Onofre1, Ana Teresa Simões2, Udaya Vijayakumar2, Beverly L Davidson3, Luís Pereira de Almeida4.   

Abstract

Machado-Joseph disease (MJD) is a genetic neurodegenerative disease caused by an expanded polyglutamine tract within the protein ataxin-3 (ATXN3). Despite current efforts, MJD's mechanism of pathogenesis remains unclear and no disease-modifying treatment is available. Therefore, in this study, we investigated (1) the role of the 3' UTR of ATXN3, a putative microRNA (miRNA) target, (2) whether miRNA biogenesis and machinery are dysfunctional in MJD, and (3) which specific miRNAs target ATXN3-3' UTR and whether they can alleviate MJD neuropathology in vivo. Our results demonstrate that endogenous miRNAs, by targeting sequences in the 3' UTR, robustly reduce ATXN3 expression and aggregation in vitro and neurodegeneration and neuroinflammation in vivo. Importantly, we found an abnormal MJD-associated downregulation of genes involved in miRNA biogenesis and silencing activity. Finally, we identified three miRNAs-mir-9, mir-181a, and mir-494-that interact with the ATXN3-3' UTR and whose expression is dysregulated in human MJD neurons and in other MJD cell and animal models. Furthermore, overexpression of these miRNAs in mice resulted in reduction of mutATXN3 levels, aggregate counts, and neuronal dysfunction. Altogether, these findings indicate that endogenous miRNAs and the 3' UTR of ATXN3 play a crucial role in MJD pathogenesis and provide a promising opportunity for MJD treatment.
Copyright © 2017 The American Society of Gene and Cell Therapy. All rights reserved.

Entities:  

Keywords:  3′; Machado-Joseph disease; SCA3; UTR; gene therapy; lentivirus; mechanism of disease; microRNA; microRNA machinery dysregulation

Mesh:

Substances:

Year:  2017        PMID: 28236575      PMCID: PMC5383579          DOI: 10.1016/j.ymthe.2017.01.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  66 in total

Review 1.  The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology?

Authors:  B Conne; A Stutz; J D Vassalli
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

3.  Structural features of microRNA (miRNA) precursors and their relevance to miRNA biogenesis and small interfering RNA/short hairpin RNA design.

Authors:  Jacek Krol; Krzysztof Sobczak; Urszula Wilczynska; Maria Drath; Anna Jasinska; Danuta Kaczynska; Wlodzimierz J Krzyzosiak
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

4.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

5.  Differential susceptibility of cultured cell lines to aggregate formation and cell death produced by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch.

Authors:  T Yoshizawa; H Yoshida; S Shoji
Journal:  Brain Res Bull       Date:  2001 Oct-Nov 1       Impact factor: 4.077

6.  Identification of tissue-specific microRNAs from mouse.

Authors:  Mariana Lagos-Quintana; Reinhard Rauhut; Abdullah Yalcin; Jutta Meyer; Winfried Lendeckel; Thomas Tuschl
Journal:  Curr Biol       Date:  2002-04-30       Impact factor: 10.834

7.  A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.

Authors:  Daniel Goti; Scott M Katzen; Jesse Mez; Noam Kurtis; Jennifer Kiluk; Lea Ben-Haïem; Nancy A Jenkins; Neal G Copeland; Akira Kakizuka; Alan H Sharp; Christopher A Ross; Peter R Mouton; Veronica Colomer
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

8.  Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.

Authors:  Annette Haacke; Sarah A Broadley; Raina Boteva; Nikolay Tzvetkov; F Ulrich Hartl; Peter Breuer
Journal:  Hum Mol Genet       Date:  2006-01-11       Impact factor: 6.150

9.  YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit.

Authors:  Cemal K Cemal; Christopher J Carroll; Lorraine Lawrence; Margaret B Lowrie; Piers Ruddle; Sahar Al-Mahdawi; Rosalind H M King; Mark A Pook; Clare Huxley; Susan Chamberlain
Journal:  Hum Mol Genet       Date:  2002-05-01       Impact factor: 6.150

10.  Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.

Authors:  Luis Pereira de Almeida; Christopher A Ross; Diana Zala; Patrick Aebischer; Nicole Déglon
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

View more
  10 in total

1.  Inhibition of histone deacetylase 3 by MiR-494 alleviates neuronal loss and improves neurological recovery in experimental stroke.

Authors:  Haiping Zhao; Guangwen Li; Sijia Zhang; Fangfang Li; Rongliang Wang; Zhen Tao; Qingfeng Ma; Ziping Han; Feng Yan; Junfen Fan; Lingzhi Li; Xunming Ji; Yumin Luo
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-11       Impact factor: 6.200

2.  Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.

Authors:  Ana Rosa Vieira Melo; Mafalda Raposo; Marta Ventura; Sandra Martins; Sara Pavão; Isabel Alonso; Conceição Bettencourt; Manuela Lima
Journal:  Cerebellum       Date:  2022-01-16       Impact factor: 3.847

3.  miRNA-Mediated Knockdown of ATXN3 Alleviates Molecular Disease Hallmarks in a Mouse Model for Spinocerebellar Ataxia Type 3.

Authors:  Rui Jorge Nobre; Diana D Lobo; Carina Henriques; Sonia P Duarte; Sara M Lopes; Ana C Silva; Miguel M Lopes; Fanny Mariet; Lukas K Schwarz; M S Baatje; Valerie Ferreira; Astrid Vallès; Luis Pereira de Almeida; Melvin M Evers; Lodewijk J A Toonen
Journal:  Nucleic Acid Ther       Date:  2021-12-07       Impact factor: 4.244

Review 4.  Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.

Authors:  Yu-Shuan Chen; Zhen-Xiang Hong; Shinn-Zong Lin; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

Review 5.  Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias.

Authors:  Ricardo Afonso-Reis; Inês T Afonso; Clévio Nóbrega
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

6.  Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo.

Authors:  David Rufino-Ramos; Sevda Lule; Shadi Mahjoum; Stefano Ughetto; D Cristopher Bragg; Luís Pereira de Almeida; Xandra O Breakefield; Koen Breyne
Journal:  Biomaterials       Date:  2022-01-08       Impact factor: 12.479

7.  Allele-specific targeting of mutant ataxin-3 by antisense oligonucleotides in SCA3-iPSC-derived neurons.

Authors:  Stefan Hauser; Jacob Helm; Melanie Kraft; Milena Korneck; Jeannette Hübener-Schmid; Ludger Schöls
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

8.  ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease.

Authors:  Ana Vasconcelos-Ferreira; Inês Morgado Martins; Diana Lobo; Dina Pereira; Miguel M Lopes; Rosário Faro; Sara M Lopes; Dineke Verbeek; Thorsten Schmidt; Clévio Nóbrega; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2021-07-21       Impact factor: 11.454

Review 9.  Polyglutamine Repeats in Viruses.

Authors:  Catherine H Schein
Journal:  Mol Neurobiol       Date:  2018-09-04       Impact factor: 5.590

10.  PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.

Authors:  Kathrin Gonsior; Gabriele Anna Kaucher; Patrik Pelz; Dorothea Schumann; Melanie Gansel; Sandra Kuhs; Thomas Klockgether; Sylvie Forlani; Alexandra Durr; Stefan Hauser; Tim W Rattay; Matthis Synofzik; Holger Hengel; Ludger Schöls; Olaf H Rieß; Jeannette Hübener-Schmid
Journal:  J Neurol       Date:  2020-10-26       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.